PE20021078A1 - Drogas peptidicas antiangiogenicas - Google Patents

Drogas peptidicas antiangiogenicas

Info

Publication number
PE20021078A1
PE20021078A1 PE2002000292A PE2002000292A PE20021078A1 PE 20021078 A1 PE20021078 A1 PE 20021078A1 PE 2002000292 A PE2002000292 A PE 2002000292A PE 2002000292 A PE2002000292 A PE 2002000292A PE 20021078 A1 PE20021078 A1 PE 20021078A1
Authority
PE
Peru
Prior art keywords
sar
arg
pro
peptidic
isoleucilo
Prior art date
Application number
PE2002000292A
Other languages
English (en)
Inventor
Jack Henkin
Douglas M Kalvin
Andew J Schneider
Michael F Bradley
Fortuna Aviv
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20021078A1 publication Critical patent/PE20021078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I N-Ac-Sar-Gly-AA3-AA4-AA5-AA6-AA7-Arg-Pro-AA10 UNA SAL ACEPTABLE, ESTER, PROFARMACO, SOLVATO DEL MISMO DONDE AA3 ES GLUTAMINILO, FENILALANILO, VALILO, ASPARAGINILO, AA4 ES D-ISOLEUCILO, ISOLEUCILO, D-LEUCILO, D-ALOISOLEUCILO, ENTRE OTROS, AA5 ES SERILO, METIONILO, TREONILO, ENTRE OTROS; AA6 ES NORVALILO, SERILO, TRIPTOFILO. UN COMPUESTO SELECCIONADO DE N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ille-Arg-Pro-D-AlaNH2, DE N-Ac-Sar-Phe-Gln-D-Ile-Thr-Nva-Ille-Arg-Pro-D-AlaNH2, ENTRE OTROS. LOS PEPTIDOS MENCIONADOS INHIBEN LA ANGIOGENESIS Y SON UTILES PARA EL TRATAMIENTO DEL CANCER
PE2002000292A 2001-04-11 2002-04-10 Drogas peptidicas antiangiogenicas PE20021078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/832,733 US20020183242A1 (en) 2001-04-11 2001-04-11 Peptide antiangiogenic drugs

Publications (1)

Publication Number Publication Date
PE20021078A1 true PE20021078A1 (es) 2002-12-18

Family

ID=25262479

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000292A PE20021078A1 (es) 2001-04-11 2002-04-10 Drogas peptidicas antiangiogenicas

Country Status (10)

Country Link
US (1) US20020183242A1 (es)
EP (1) EP1429796A4 (es)
JP (1) JP2005510452A (es)
AU (1) AU2002303278A1 (es)
BR (1) BR0205983A (es)
CA (1) CA2443733A1 (es)
MX (1) MXPA03009278A (es)
PE (1) PE20021078A1 (es)
UY (1) UY27254A1 (es)
WO (1) WO2002083065A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US20080152660A1 (en) 2005-03-03 2008-06-26 Bradshaw Curt W Anti-Angiogenic Compounds
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2705035B1 (en) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
MX2015005734A (es) 2012-11-05 2016-02-10 Zafgen Inc Metodos de tratamiento de enfermedades hepaticas.
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200937A (en) * 1988-09-29 1993-04-06 Canon Kabushiki Kaisha Apparatus for and method of recording and/or reproducing information by means of two actuators
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
PT918795E (pt) * 1997-03-17 2005-02-28 Abbott Lab Droga antiangiogenica para tratar cancro artrite e retinopatia
PT1078002E (pt) * 1998-05-22 2008-09-02 Abbott Lab Fármacos de péptidos antiangiogénicos
MXPA02005150A (es) * 1999-11-22 2003-01-28 Abbott Lab Peptidos que tienen actividad antiangiogenica.
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica

Also Published As

Publication number Publication date
US20020183242A1 (en) 2002-12-05
MXPA03009278A (es) 2004-03-10
EP1429796A4 (en) 2005-01-12
JP2005510452A (ja) 2005-04-21
UY27254A1 (es) 2002-11-29
AU2002303278A1 (en) 2002-10-28
BR0205983A (pt) 2006-05-23
WO2002083065A3 (en) 2004-01-08
CA2443733A1 (en) 2002-10-24
EP1429796A2 (en) 2004-06-23
WO2002083065A2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
PE20021078A1 (es) Drogas peptidicas antiangiogenicas
ES2181752T3 (es) Conjugados de agentes antitumorales de metiltritio y productos intermedios para su sintesis.
DE69810283D1 (de) GnRH ANTAGONISTEN
PE20230782A1 (es) Compuestos y su uso en el tratamiento del cancer
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
UY25074A1 (es) Inhibidores de la farnesil proteina transferasa
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
AR028451A1 (es) Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento
CR6939A (es) Polimorfo de monohidrato de zopolrestat
EA200800067A1 (ru) Нестероидные антиандрогены, направленные на 12 спираль (рецептора андрогенов)
ATE438445T1 (de) Zubereitung enthaltend nanopartikuläres uv- schutzmittel
PE84999A1 (es) Analogos del peptido lh-rh y composiciones farmaceuticas que los contienen
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
UY26889A1 (es) Compuestos farmacéuticos
AR008907A1 (es) Conjugados utiles en el tratamiento del cancer de prostata
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
AR033804A1 (es) Antagonistas de gnrh y sus aplicaciones
ES2195089T3 (es) Benzotiofenos amorfos, procedimientos de preparacion y uso.
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
AR028411A1 (es) Secuencias de nuclentidos relacionadas con el aumento o la disminucion del endice de ovulacion en mameferos
ITMI992481A0 (it) Isolatore passante a semi-condensatore del tipo a riempimento di gas i solante quale sf6
AR030752A1 (es) Procedimiento para la isomerizacion de alcoholes alilicos

Legal Events

Date Code Title Description
FX Voluntary withdrawal